EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention

Giovanni Pagano, Alex Lyakhovich, Philippe J Thomas, Federico V Pallardó Catalayud, Luca Tiano, Adriana Zatterale, Marco Trifuoggi

Inflammopharmacology · 2025

DOI: 10.1007/s10787-024-01613-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Giovanni Pagano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Sciences, Federico II Naples University, 80136, Naples, Italy. paganog756@gmail.com. Hauptthemen laut MEDLINE: Neoplasms, Anti-Inflammatory Agents, Antineoplastic Agents, Mitochondria. Die Arbeit nennt 120 Literaturangaben. Gefördert von: TUBITAK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An extensive body of literature has associated cancer with redox imbalance and inflammatory conditions. Thus, several studies and current clinical practice have relied on the use of anticancer drugs known to be associated with prooxidant state. On the other hand, a number of studies have reported on the effects of several antioxidants, anti-inflammatory agents and of mitochondrial cofactors (also termed mitochondrial nutrients, MNs) in counteracting or slowing carcinogenesis, or in controlling cancer growth. In the available literature, a body of evidence points on the roles of anti-inflammatory agents and of individual MNs against carcinogenesis or in controlling cancer cell proliferation, but only a few reports on the combined use of two or the effect of three MNs. These combinations are proposed as potentially successful tools to counteract carcinogenesis in prospective animal model studies or in adjuvant cancer treatment strategies. A "triad" of MNs are suggested to restore redox balance, mitigate side effects of prooxidative anticancer drugs, or aid in cancer prevention and/or adjuvant therapy. By elucidating their mechanistic underpinnings and appraising their clinical efficacy, we aim to contribute with a comprehensive understanding of these therapeutic modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAnti-Inflammatory AgentsAntineoplastic AgentsMitochondriaHumansAnimalsAntioxidantsOxidation-ReductionOxidative StressReactive Oxygen Species

Stichwörter der Autor:innen

l-CarnitineAlpha-lipoic acidAnti-inflammatoryCancerCoenzyme Q10Mitochondria

Substanzen

Anti-Inflammatory AgentsAntineoplastic AgentsAntioxidantsReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Chemical Sciences, Federico II Naples University, 80136, Naples, Italy. paganog756@gmail.com.
  • Sabanci University, Tuzla, 34956, Istanbul, Turkey.
  • Environment and Climate Change Canada, Science Technology Branch, National Wildlife Research Center - Carleton University, Ottawa, ON, K1A 0H3, Canada.
  • Instituto de Investigación Sanitaria INCLIVA, 46010, Valencia, Spain.
  • Department of Life and Environmental Sciences, Polytechnical University of Marche, Ancona, Italy.
  • ASL Napoli 1, Naples, Italy.

Förderung

  • TUBITAK

Zitieren

APA

Pagano, G., Lyakhovich, A., Thomas, P. J., Catalayud, F. V. P., Tiano, L., Zatterale, A., & Trifuoggi, M. (2025). Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01613-w

Vancouver

Pagano G, Lyakhovich A, Thomas PJ, Catalayud FVP, Tiano L, Zatterale A, et al. Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention. Inflammopharmacology. 2025. doi:10.1007/s10787-024-01613-w

BibTeX
@article{Pagano2025,
  author = {Pagano, Giovanni and Lyakhovich, Alex and Thomas, Philippe J and Catalayud, Federico V Pallardó and Tiano, Luca and Zatterale, Adriana and Trifuoggi, Marco},
  title = {Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-024-01613-w}
}
Kostenlos starten →